Tyvaso DPI Interactions
There are 321 drugs known to interact with Tyvaso DPI (treprostinil), along with 7 disease interactions. Of the total drug interactions, 30 are major, 287 are moderate, and 4 are minor.
- View all 321 medications that may interact with Tyvaso DPI
- View Tyvaso DPI disease interactions (7)
Most frequently checked interactions
View interaction reports for Tyvaso DPI (treprostinil) and the medicines listed below.
- albuterol
- albuterol / ipratropium
- alprazolam
- ambrisentan
- amlodipine
- atorvastatin
- budesonide
- Bumex (bumetanide)
- buspirone
- calcium / vitamin d
- carvedilol
- doxycycline
- furosemide
- gabapentin
- Imodium (loperamide)
- Lasix (furosemide)
- levothyroxine
- lisinopril
- losartan
- melatonin
- mycophenolate mofetil
- Ofev (nintedanib)
- oxygen
- pantoprazole
- potassium chloride
- prednisone
- sertraline
- sildenafil
- tadalafil
- Vitamin D3 (cholecalciferol)
Tyvaso DPI disease interactions
There are 7 disease interactions with Tyvaso DPI (treprostinil) which include:
- hepatic impairment
- bleeding
- diverticulosis
- hypotension
- liver dysfunction
- pulmonary infections
- renal dysfunction
More about Tyvaso DPI (treprostinil)
- Tyvaso DPI consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: agents for pulmonary hypertension
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.